XTALPI (XtalPi Holdings Limited) announced 2025 results showing a sharp swing to profitability and rapid top-line expansion driven by its AI-enabled drug discovery and intelligent solutions businesses.

Revenue climbed 201.2% year on year to RMB 802.62 million, lifted by:

• Drug Discovery Solutions: RMB 537.93 million, up 418.9%, boosted by antibody projects and milestone deliveries across several innovative pipelines. • AI for Science (AI4S) Intelligent Solutions: RMB 264.69 million, up 62.6%, reflecting wider customer adoption of robotic labs and integrated AI services.

The company recorded its first full-year profit, with net income of RMB 134.58 million versus a RMB 1.51 billion loss in 2024. Adjusted net profit (excluding convertible-share revaluation, share-based compensation, and listing expenses) reached RMB 258.16 million, compared with an adjusted loss of RMB 456.80 million a year earlier.

Key cost and income items • Research & Development expenses rose 36.1% to RMB 569.19 million as the firm expanded its AI model portfolio to more than 200 domain-specific models and advanced new modality platforms (molecular glue, peptide, oligonucleotide). • General & Administrative expenses edged down 1.9% to RMB 409.89 million, reflecting the absence of listing costs recorded in 2024. • Other gains surged to RMB 514.04 million (2024: RMB 34.79 million), mainly from fair-value increases in financial assets. • Operating profit reached RMB 55.24 million versus a RMB 684.21 million loss in 2024. Finance income doubled to RMB 111.65 million on higher deposit balances.

Cash and balance sheet • Cash balance (cash, equivalents, bank deposits, current financial assets and restricted cash) stood at RMB 7.07 billion at 31 December 2025. • Net cash from financing activities totalled RMB 5.57 billion, mainly from two share placings. • Capital expenditure was RMB 74.40 million, focused on robotic laboratories and intangible assets. • Bank borrowings increased to RMB 345.80 million, all at fixed rates. The gearing ratio remained nil as cash exceeded debt by RMB 6.72 billion.

Corporate activity • Acquired 90% of Shanghai Siwei Medical Technology for RMB 250 million, adding imaging-based AI diagnostic capabilities. • Post year-end, issued HKD 2.87 billion (net HKD 2.84 billion) zero-coupon convertible bonds on 28 January 2026 to expand the AI-for-Science platform.

Outlook Management highlighted continued scale-up of its “AI + Robotics + Multi-Agent” flywheel, aiming to extend applications beyond biopharma into consumer health, photovoltaics and advanced materials, underpinned by robust cash reserves and inclusion in multiple MSCI and HKEX tech indices.